CT053PTSA

DRUG5 trials

Sponsors

Sunshine Lake Pharma Co., Ltd.

Conditions

Acute Myeloid Leukemia (AML)Advanced NSCLCAdvanced Solid TumorsNon-small Cell Lung CancerRenal Cell Cancer Metastatic

Phase 1

A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)

TerminatedNCT03125876

Sunshine Lake Pharma Co., Ltd.Acute Myeloid Leukemia (AML)

Start: 2017-11-13End: 2019-08-19Updated: 2021-03-24

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

CompletedNCT03758287

Sunshine Lake Pharma Co., Ltd.Non-small Cell Lung Cancer

Start: 2016-11-01End: 2021-09-17Updated: 2026-05-12

A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC

TerminatedNCT03876925

Sunshine Lake Pharma Co., Ltd.Renal Cell Cancer Metastatic

Start: 2018-06-25End: 2020-05-12Updated: 2021-03-24

First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors

CompletedNCT04577703

Sunshine Lake Pharma Co., Ltd.Advanced Solid Tumors

Start: 2014-02-08End: 2015-12-10Updated: 2020-10-08

Phase 2

Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations

WithdrawnNCT04992858

Sunshine Lake Pharma Co., Ltd.Advanced NSCLC

Start: 2022-11-27End: 2024-12-09Updated: 2026-05-14

Related Papers

A phase Ib study of a novel c-MET, AXL and VEGFR-2 inhibitor ningetinib and gefitinib combination therapy in Chinese EGFR-TKI resistant NSCLC with T790M negative.

Journal of Clinical Oncology2020-05-204 citations